Business Wire

IntegenX Applauds the Passage of the Rapid DNA Act of 2017

Jaa

IntegenX Inc., the global market leader for Rapid DNA human identification, applauds the signing into law of S.139 and HR.510, The Rapid DNA Act of 2017. The legislation will allow law enforcement agencies, under standards and guidelines established by the FBI, to perform real-time DNA testing at time of arrest, within booking stations.

Similar to how fingerprint analysis has evolved from a paper and ink practice to a point-of-action technology, DNA testing has now become possible in 90 minutes within a booking station, while a suspect is still in custody. With processing times reduced from weeks to less than two hours, the potential to identify or exonerate a suspect quickly will make a meaningful impact on law enforcement.

IntegenX thanks U.S. Senate sponsor Senator Orrin Hatch (R-UT) and lead co-sponsor Senator Dianne Feinstein (D-CA) as well as House sponsor Congressman James Sensenbrenner (R-WI) and lead co-sponsor Congressman Eric Swalwell (D-CA), along with the other 12 Senate and 24 House co-sponsors for their support.

“Today marks a landmark day in more efficiently fighting crime and supporting law enforcement,” stated Robert Schueren, President and CEO of IntegenX. “IntegenX products have already enabled numerous DNA profile uploads to our nation’s DNA database (CODIS). We look forward to the updated FBI guidelines, and subsequent CODIS uploads from the booking environment.”

“Rapid DNA is a promising new technology and an effective tool for law enforcement – I’m thrilled to be seeing it signed into law. This technology will help quickly identify arrestees and offenders, reduce the overwhelming backlog in forensic DNA analysis, and make crime fighting more efficient while helping to prevent future crimes from occurring. It will also save time and taxpayer dollars,” commented Congressman Sensenbrenner, Chairman of the House Judiciary Subcommittee on Crime, Terrorism, Homeland Security and Oversight.

“This bill will help law enforcement agencies solve crimes faster and help those wrongfully accused to be exonerated from crimes they did not commit—almost instantly. The Rapid DNA Act updates the statutory framework in how DNA samples are entered into the FBI’s Combined DNA Index System by allowing the use of this remarkable Rapid DNA technology,” stated Senator Hatch.

“I’m glad we were able to reach bipartisan consensus to enact this law. This new law will help law enforcement agencies across the nation use a faster and more powerful tool to protect and serve our communities, and to attain justice for victims,” said Congressman Swalwell (D-CA).

“I applaud the passage of the Rapid DNA Act by the U.S. Congress. This update to current DNA law, enabling use of Rapid DNA analysis by our local law enforcement officials, is a tremendous victory for our communities, bringing swift justice to survivors of sexual assault and helping to prevent assaults by repeat offenders,” said Debbie Smith, founder of H-E-A-R-T, Inc. (Hope Exists After Rape Trauma). “I believe that this Act will help free up crime laboratory resources, allowing them to be more focused on the testing of backlogged rape kits, a problem that together with Congress, we have been working on for the past 15 years.”

“We’re very excited to see the passage of the Rapid DNA Act of 2017,” said Mai Fernandez, Executive Director of National Center for Victims of Crime. “Having results for DNA tests while suspects are still in custody should further contribute to the safety of our communities, and ultimately potentially reduce rape kit backlog.”

To further facilitate the adoption and validation of Rapid DNA technology by state forensic laboratories conducting arrestee testing, IntegenX is announcing the “Act in 2017” program, providing state forensic laboratories with cost-effective introductory pricing of the RapidHIT ID System and RapidLINK software. The RapidHIT ID system’s pivotal development validation study was recently published in the prestigious Forensic Science International: Genetics http://www.fsigenetics.com/article/S1872-4973(17)30005-4/pdf

About IntegenX

IntegenX Inc. is the market leader of Rapid Human DNA identification technology. IntegenX technology platforms integrate advanced fluidics, optics, and biochemistry capabilities, along with cutting edge software, to produce sample-to-answer products for DNA-based human identity testing for forensics and law enforcement applications. For more information, please visit www.integenx.com. IntegenX, the IntegenX logo, RapidHIT, and RapidLINK are the registered trademarks of IntegenX Inc.

Contact information

IntegenX Inc.
David V. Smith, 925-701-3400
Chief Operating Officer
davids@integenx.com
Fax: 925-574-7373

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Citi Private Bank Congratulates Fernando Alonso on the 24 Hours of Le Mans Win18.6.2018 17:01Tiedote

Citi Private Bank ardently congratulates Fernando Alonso for his impressive win at The 24 Hours of Le Mans this past weekend. Mr. Alonso, who is also a two time Formula One World Champion, most recently competed and won the Six Hours of Spa-Francorchamps in May. In January he debuted at the Rolex 24 at Daytona. Previously he participated in the Indianapolis 500 in May of 2017. He was sponsored by Citi Private Bank for all four races. Alongside the Indianapolis 500 and the Monaco Grand Prix, Le Mans makes up one third of ‘the Triple Crown of Motor Racing’. Having already won Monaco twice, Mr. Alonso is on a quest to become only the second driver in history to complete the Triple Crown. “Fernando drove one the most thrilling races at Le Mans that I have ever seen. His stunning night time drive will likely go down as one of the greatest victories in motorsport’s history,” said Peter Clive Charrington, Global Head of Citi Private Bank. “Fernando possesses an unrelenting drive toward excell

Inteva Products Receives Top Innovation Award for Revolutionary Stitching Process18.6.2018 16:31Tiedote

Inteva Products, LLC, a leading global Tier One automotive supplier of engineered components and systems, received the top prize in the 2018 Innovation Awards presented by the European Association of Automotive Suppliers (CLEPA) at The Hague, Netherlands, on June 13. Inteva was recognized for its new real-time scanning process for the robotic stitching of automotive interiors. This innovative technology will be used on instrument panels for the 2019 Chevrolet Silverado and GMC Sierra pickup trucks. The new process enables “live” scanning and immediate adjustments to the program path of robotic stitching equipment as a component is being stitched. This approach aligns leading-edge advances in the use of lasers in automotive manufacturing with Inteva’s unique robotic stitching technologies. The advancement reduces the average cycle time of a stitched surface by approximately 20-30%. The 2018 CLEPA Innovation Awards, organized in cooperation with Deloitte, celebrate automotive excellence

P&G Advances Systemic Change for Gender Equality in Advertising at 2018 Cannes Lions Festival of Creativity18.6.2018 15:25Tiedote

The Procter & Gamble Company (NYSE: PG) today advanced its commitment to gender equality through a series of new actions, commitments and partnerships to increase diversity throughout the creative supply chain, leading to more accurate and positive portrayals of women in advertising and media, and driving growth and social good. Women and girls are inaccurately or negatively portrayed in 29 percent of ads and media programs*, and women continue to be underrepresented behind the camera: only 32 percent of Chief Marketing Officers, 33 percent of Chief Creative Officers and a mere 10 percent of Commercial Directors are women. These issues persist despite evidence that gender-equal ads perform 10 percent higher in trust and 26 percent higher in sales growth*. To address these issues, P&G has called for an aspiration to achieve 100% accurate and positive portrayals of women in advertising and media, supported by equal representation of women and men in the creative supply chain. P&G is lead

Norsk Titanium Marks Milestone in U.S. Production18.6.2018 15:00Tiedote

Norsk Titanium (NTi), the world’s first FAA-approved supplier of aerospace-grade, additive manufactured, structural titanium components, announced today a major milestone in qualified production. NTi’s Plattsburgh, New York Development and Qualification Center (PDQC) site was officially added to Boeing’s Qualified Producers List (QPL) on May 1 and initiated qualified production on May 15 by manufacturing its first part under the Boeing contract. This milestone is a culmination of recent company successes including certification under AS9100D and the October 2017 dedication of PDQC by New York Governor Andrew Cuomo. “We could not be prouder of our Plattsburgh, New York production operations as they put another stake in the ground for the continued success of Norsk Titanium and the state of New York,” said NTi’s Chief Operating Officer Tamara Morytko. “Receiving this qualification from Boeing, now qualifying two NTi sites for production across the globe, is a true vote of confidence in o

Avedro Announces Enrollment of First Patient in U.S. Pivotal Phase 3 Epi-on Corneal Cross-Linking Trial for Progressive Keratoconus18.6.2018 15:00Tiedote

Avedro, Inc., an ophthalmic pharmaceutical and medical device company and the world leader in corneal remodeling, today announced that it has begun enrolling patients in a pivotal Phase 3 clinical trial to evaluate the safety and efficacy of an epithelium-on (epi-on) corneal collagen cross-linking procedure to treat patients with progressive keratoconus. Keratoconus is a non-inflammatory eye condition in which the typically round dome-shaped cornea progressively thins and weakens and is the leading cause of penetrating keratoplasty (corneal transplant) in the United States1. The Phase 3 clinical trial, ACP-KXL-308, is a multicenter, randomized, controlled study of a novel corneal cross-linking procedure of 275 patients with progressive keratoconus across approximately 20 sites in the United States. As is typical for U.S. Food and Drug Administration (FDA) drug trials, investigational treatments are provided at no cost to participating patients. “As a practitioner who has treated many p

LG Chem Hosts Global Innovation Contest 2018 (GIC 2018)"Finding Innovations to Change the World"18.6.2018 14:00Tiedote

LG Chem (KRX: 051910) is exploring innovative technologies that will change the world. LG Chem announced that it would hold a Global Innovation Contest (GIC) for leading universities and research institutions around the world. This is the first time that a Korean chemical company is conducting technology contests for the entire world. From June 18th to September 30th, 2018, LG Chem will accept innovative technology ideas in five promising business areas: Energy, Environment, Functional materials, Bio technology and Platform technology. Global scholars and researchers who are interested in developing the next generation’s innovative technology and industry-academia collaboration research are welcomed to participate and submit the technical proposal through the official website (www.rnd.lgchem.com/global/gic). LG Chem will select internal experts and selection committees to evaluate the proposals considering technology innovation, marketability, and price competitiveness. Selected assign

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme